Company Filing History:
Years Active: 2015
Title: Holly Mead: Innovator in Vaccine Development
Introduction
Holly Mead is a prominent inventor based in Plano, TX (US). She has made significant contributions to the field of vaccine development, particularly in the area of HIV research. Her innovative work has led to the creation of a unique vaccine that aims to elicit a robust immune response against HIV.
Latest Patents
Holly Mead holds a patent for a dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef. This invention includes compositions and methods for making and using a vaccine that incorporates a DC-specific antibody or fragment to which an engineered Gag antigen is attached. The Gag antigen is designed to be less susceptible to proteolytic degradation, enhancing the vaccine's effectiveness. The vaccine aims to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef, and/or Cyclin D1.
Career Highlights
Throughout her career, Holly has worked with esteemed organizations such as Baylor Research Institute and the Institut National De La Santé Et De La Recherche Médicale. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Holly has collaborated with notable colleagues, including Jacques F. Banchereau and Gerard Zurawski. These partnerships have further enriched her research and development efforts in vaccine technology.
Conclusion
Holly Mead's innovative work in vaccine development showcases her dedication to advancing medical science. Her contributions are vital in the ongoing fight against HIV, and her patent reflects her commitment to improving public health.